Clinical Edge Journal Scan

Atopic dermatitis shortens biologic-free survival in inflammatory bowel disease


 

Key clinical point: Presence of concurrent atopic dermatitis (AD) significantly affects the biologic-free survival in patients with inflammatory bowel disease (IBD).

Major finding: Presence of concurrent AD was associated with a significantly shorter biologic-free survival in patients with IBD (adjusted hazard ratio [aHR] 1.743; P = .032), with the association being stronger in patients with ulcerative colitis (aHR 4.769; P = .004).

Study details: Findings are from a retrospective study including 61 adult patients with IBD and concurrent AD and 122 matched control individuals with IBD alone.

Disclosures: This study was supported by the National Research Foundation of Korea grant funded by the Korea government and others. The authors declared no conflicts of interest.

Source: Kim KW, et al, and Seoul National University Inflammatory Bowel Disease Research Network (SIRN) and Inflammatory Bowel Disease Research Group of Korean Association for the Study of Intestinal Disease (KASID). Atopic dermatitis is associated with the clinical course of inflammatory bowel disease. Scand J Gastroenterol. 2023;1-7 (May 11). doi: 10.1080/00365521.2023.2209688

Recommended Reading

Advising patients on AD treatment options: Expert pearls
MDedge Dermatology
A live topical biotherapeutic spray improves pruritus in atopic dermatitis
MDedge Dermatology
Atopic dermatitis positively linked with the risk for incident venous thromboembolism
MDedge Dermatology
Crisaborole once daily an effective long-term maintenance therapy for atopic dermatitis
MDedge Dermatology
Switching to upadacitinib from dupilumab improves atopic dermatitis
MDedge Dermatology
Successful dupilumab dose tapering in controlled atopic dermatitis
MDedge Dermatology
Abrocitinib improves outcomes in severe or difficult-to-treat atopic dermatitis
MDedge Dermatology
Early emollient use does not lower the odds of atopic dermatitis in high-risk infants
MDedge Dermatology
Meta-analysis reveals that abrocitinib and upadacitinib top dupilumab in moderate-to-severe atopic dermatitis
MDedge Dermatology
Dupilumab ameliorates disease signs and symptoms in children with severe atopic dermatitis
MDedge Dermatology